The "e"s have it
Executive Summary
Novartis' investigational cancer agent imatinib trade name is changed in U.S. from "Glivec" to "Gleevec" to avoid possible confusion with Pharmacia's diabetes drug Glyset, Novartis says. The name "Glivec" will continue to be used in all other countries where applications have been submitted. The Gleevec NDA was filed Feb. 27 for second-line treatment of chronic myeloid leukemia and is receiving a priority review
You may also be interested in...
Novartis Gleevec For Leukemia Will Be In Pharmacies By Mid-May
Novartis' chronic myeloid leukemia therapy Gleevec will be available in pharmacies by the time oncologists return from the American Society of Clinical Oncology May 12-15 meeting.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011